Skip to content

Advertisement

  • Meeting abstract
  • Open Access

Enhanced fear expression in a psychphathological mouse model of trait anxiety: pharmacological interventions

  • 1,
  • 1,
  • 2, 3,
  • 1,
  • 2 and
  • 1Email author
BMC Pharmacology201010 (Suppl 1) :A5

https://doi.org/10.1186/1471-2210-10-S1-A5

  • Published:

Keywords

  • Anxiety Disorder
  • Trait Anxiety
  • Fear Conditioning
  • Mouse Line
  • Fear Memory

Background

The propensity to develop an anxiety disorder is thought to be determined by genetic and environmental factors. Here we investigated the relationship between an extreme genetic predisposition to trait anxiety and experience-based learned fear in a psychopathological mouse model.

Methods

Male CD-1 mice selectively bred for either high (HAB) or normal (NAB) anxiety-related behaviour on the elevated plus maze were subjected to classical fear conditioning.

Results

Both mouse lines learned to fear an initially neutral stimulus (CS) being indicated by increasing freezing levels. 24 h later, HAB mice displayed more pronounced freezing responses to both the context and cue CS compared with NAB mice, suggesting that trait anxiety determines stronger fear memory and/or a weaker ability to inhibit fear responses in the HAB line. Interestingly, already 1 h and 6 h after fear conditioning, freezing levels were high in HAB mice but not in NAB mice. The enhanced fear response of HAB mice was attenuated by treatment with either the α2,3,5-subunit-selective benzodiazepine partial agonist L-838,417, corticosterone or the selective neurokinin-1 receptor antagonist L-822,429.

Conclusions

Overall, the HAB mouse line may represent an interesting model (i) for identifying biological factors underlying misguided conditioned fear responses and (ii) for studying novel pharmacotherapies for patients with anxiety disorders, including post-traumatic stress disorder and phobias.

Declarations

Acknowledgements

Supported by the Austrian Science Fund FWF NFN-S-102 (NS).

Authors’ Affiliations

(1)
Department of Pharmacology and Toxicology, Institute of Pharmacy and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, 6020 Innsbruck, Austria
(2)
Department of Behavioral Neuroendocrinology, Max Planck Institute of Psychiatry, 80804 Munich, Germany
(3)
Affectis Pharmaceuticals AG, 82152 Martinsried, Germany

Copyright

© Singewald et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.

Advertisement